Skip to main navigation
Menu
Main navigation
Advocacy
Issue Overview
#Rx4StateSavings
#4GRxANTED
#MarkupMadness
State Advocacy
GDUFA/BsUFA User Fees
Biosimilars Council
Action Center
Our Impact
Join
About Us
Generic Quality
About AAM
Our Team
Our Members
Generic Medicines
Biosimilars Council
Meet Our Board
Social Commitment
Careers
Contact Us
Stories
Events
Access! 2025
GRx+Biosims 2024
Resources
All Resources
Drug Shortages White Paper
2023 Savings Report
Biosimilars Patient Resource Center
Biosimilar Research & Studies
Press Releases
Blog
Founders Blogs
Amicus Briefs
Take Action
Search
Close
Breadcrumb
Association for Accessible Medicines
Resources
Resources
Share
Find up-to-date information on generics and biosimilars
Filter Resources
Issues
Biosimilar User Fee Act (BsUFA)
Biosimilars
Complex Generics
Drug Approval Process (GDUFA)
Drug Prices
Drug Shortages
Generic Drug Labeling
Generic Supply Chain
IP Issues
Low Income Subsidies (LIS in Part D)
Medicaid
Medicare
NAFTA
Patent Reform
Patient Stories
Pharmaceutical Waste Take Back
Preventing Drug Abuse
Quality
REMS/Sample Acquisition Remedies
State Initiatives
Tariffs
Trade
Transparency
User Fees
Resource Type
Blog
Amicus Brief
Press Release
Infographic
Video
Report
Fact Sheet
Presentation
Video
Jun 3, 2022
| Erica Klinger
GDUFA and BsUFA User Fees
Video
May 31, 2022
| Erica Klinger
Teva USA is #RemarkablyGeneric
Blog
May 31, 2022
| Erica Klinger
Everything You Need to Know About Biosimilars – All in One Place
Video
May 24, 2022
| Erica Klinger
Sandoz US is #RemarkablyGeneric
Blog
May 23, 2022
| Monét Stanford
AAM Calls for Federal Trade Commission to Investigate PBM Business Practices
Press Release
May 23, 2022
| Allen Goldberg
AAM Statement in Response to Federal Trade Commission Request for Information on PBM Business Practices
Press Release
May 16, 2022
| Allen Goldberg
Association for Accessible Medicines Names Craig Burton as Senior Vice President, Policy & Strategic Alliances, and Executive Director of the Biosimilars Council
Press Release
May 11, 2022
| Allen Goldberg
AAM Statement on House Energy and Commerce Health Subcommittee Markup of H.R. 7667 Reauthorizing Generic Drug and Biosimilar User Fee Amendments
Blog
May 2, 2022
| Monét Stanford
Generics Drive Savings Yet Patients Continue to Pay More
Video
Apr 28, 2022
| Erica Klinger
GRx+Biosims 2022
Blog
Apr 19, 2022
| Monét Stanford
As Health Care Spending in US Projected to Increase, Generics and Biosimilars Expected to Moderate Growth
Blog
Apr 19, 2022
| Monét Stanford
Challenges & Solutions for Prescription Drug Savings Identified by MedPAC
Load More
Advocacy
Issue Overview
#Rx4StateSavings
#4GRxANTED
#MarkupMadness
State Advocacy
GDUFA/BsUFA User Fees
Biosimilars Council
Action Center
Our Impact
Join
About Us
Generic Quality
About AAM
Our Team
Our Members
Generic Medicines
Biosimilars Council
Meet Our Board
Social Commitment
Careers
Contact Us
Stories
Events
Access! 2025
GRx+Biosims 2024
Resources
All Resources
Drug Shortages White Paper
2023 Savings Report
Biosimilars Patient Resource Center
Biosimilar Research & Studies
Press Releases
Blog
Founders Blogs
Amicus Briefs
Take Action